|drug2604||Postpartum women under investigation for Coronavirus or diagnosed with COVID-19 Wiki||1.00|
|drug3628||Vitamin C Wiki||0.26|
There is one clinical trial.
PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY) is a prospective cohort study of pregnant and recently pregnant women who are: either patients under investigation for COVID-19 or a confirmed case of COVID-19. Data from PRIORITY will be used to evaluate the impact of COVID-19 on the clinical course and pregnancy outcomes of pregnant women and women within 6 weeks of pregnancy.
Description: presenting symptoms and testingMeasure: Clinical presentation Time: Baseline to 12 months
Description: Clinical outcomes with resolution of illnessMeasure: Disease prognosis outcomes Time: Baseline to 12 months
Description: Pregnancy outcomes among women infected with COVID-19Measure: Pregnancy outcomes Time: Baseline to 12 months
Description: Obstetric outcomes among women infected with COVID-19Measure: Obstetric outcomes Time: Baseline to 12 months
Description: Neonatal outcomes among infants born to women with COVID-19Measure: Neonatal outcomes Time: Baseline to 12 months
Description: Transmission of COVID-19 from mother to infantMeasure: Modes of transmission of COVID-19 Time: Baseline to 12 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports